HCPLive Network

Fred Poordad, MD, on Ethnic Differences in Telaprevir Treatment Effect

In this video Fred Poordad, MD, Chief of Hepatology and Liver Transplantation at the Comprehensive Transplant Center at Cedars-Sinai Medical Center evaluates the effect of race on the response to treatment and viral resistance profiles with telaprevir combination therapy.


Related Videos
Although the treatment options for patients with both the hepatitis C virus (HCV) and HIV are mostly the same, response rates can be lower, according to Richard Sterling, MD.
Lawrence Friedman, MD, the chair of the Digestive Disease Week Council, explains how the 4 program committees selected the highlighted abstracts and sessions they believe will be of most interest not only to gastroenterologists and surgeons, but also patients.
In this video, Ira Jacobson, MD, chief of the division of gastroenterology and hepatology at Weill Medical College of Cornell University, discusses the new standard of care for hepatitis C patients: triple therapy including one of the recently approved protease inhibitors (telaprevir or boceprevir) along with pegylated interferon and ribavirin.